Boehringer Ingelheim: Embryonic stem cells and animal models

January 2010. Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim evaluates prospects for animal models and stem cell technologies. What are corporate responsibilities specific for this area? What does the company expect from embryonic stem cells?Reading time: 3 min

Read Now:
1,00 EUR (incl. 7% VAT)

Back to section